|
業務類別
|
Biotechnology |
|
業務概覽
|
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases. |
| 公司地址
| 14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6 |
| 電話號碼
| +1 250 744-2487 |
| 傳真號碼
| +1 604 369-4115 |
| 公司網頁
| https://www.auriniapharma.com |
| 員工數量
| 128 |
| Mr. Stephen P. Robertson |
Chief Legal Officer, Corporate Secretary and Chief Compliance Officer |
美元 481.90K |
21/04/2026 |
| Mr. Stewart M. Kroll |
Chief Development Officer |
-- |
23/03/2026 |
| Mr. Thomas Wei |
Chief Scientific Officer |
-- |
23/03/2026 |
| Mr. Michael S. Hearne |
Chief Financial Officer and Principal Accounting Officer |
-- |
23/03/2026 |
| Mr. Ryan Cole |
Chief Operating Officer |
-- |
23/03/2026 |
| Mr. Kevin C. Tang |
Chief Executive Officer and Chairman of the Board |
-- |
23/03/2026 |
|
|
| Ms. Kathy Goetz |
Independent Director |
21/04/2026 |
| Dr. Tina S. Nova, PhD |
Independent Director |
21/04/2026 |
| Mr. Craig A. Johnson |
Lead Independent Director |
23/03/2026 |
| Mr. Jeffrey Allen Bailey |
Independent Director |
21/04/2026 |
| Mr. Kevin C. Tang |
Chief Executive Officer and Chairman of the Board |
23/03/2026 |
|
|
|
|
